ADMA Biologics Inc. [NASDAQ: ADMA] stock went on an upward path that rose over 6.97% on Wednesday, amounting to a one-week price increase of more than 5.39%. The company report on May 11, 2022 that ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021.
Increases Full Year 2022 Total Revenue Guidance to $130 Million or More From $125 Million.
Over the last 12 months, ADMA stock rose by 16.85%. The one-year ADMA Biologics Inc. stock forecast points to a potential upside of 58.01. The average equity rating for ADMA stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $420.05 million, with 195.87 million shares outstanding and 176.93 million shares in the current float. Compared to the average trading volume of 2.72M shares, ADMA stock reached a trading volume of 3843064 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on ADMA Biologics Inc. [ADMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADMA shares is $5.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADMA stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for ADMA Biologics Inc. shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on November 11, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on November 09, 2021, representing the official price target for ADMA Biologics Inc. stock. Previously, the target price had yet another raise to $8, while Jefferies analysts kept a Buy rating on ADMA stock. On April 15, 2019, analysts increased their price target for ADMA shares from 10 to 13.
The Average True Range (ATR) for ADMA Biologics Inc. is set at 0.15, with the Price to Sales ratio for ADMA stock in the period of the last 12 months amounting to 4.47. The Price to Book ratio for the last quarter was 3.31, with the Price to Cash per share for the same quarter was set at 0.36.
ADMA Stock Performance Analysis:
ADMA Biologics Inc. [ADMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.39. With this latest performance, ADMA shares gained by 39.61% in over the last four-week period, additionally plugging by 58.09% over the last 6 months – not to mention a rise of 16.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADMA stock in for the last two-week period is set at 59.63, with the RSI for the last a single of trading hit 63.05, and the three-weeks RSI is set at 57.82 for ADMA Biologics Inc. [ADMA]. The present Moving Average for the last 50 days of trading for this stock 1.94, while it was recorded at 2.01 for the last single week of trading, and 1.53 for the last 200 days.
Insight into ADMA Biologics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and ADMA Biologics Inc. [ADMA] shares currently have an operating margin of -72.41 and a Gross Margin at +0.57. ADMA Biologics Inc.’s Net Margin is presently recorded at -88.52.
Return on Equity for this stock declined to -62.46, with Return on Assets sitting at -29.61.
ADMA Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 7.60.
ADMA Biologics Inc. [ADMA] Insider Position Details
There are presently around $226 million, or 64.70% of ADMA stock, in the hands of institutional investors. The top three institutional holders of ADMA stocks are: PERCEPTIVE ADVISORS LLC with ownership of 11,933,387, which is approximately 0% of the company’s market cap and around 2.10% of the total institutional ownership; BOOTHBAY FUND MANAGEMENT, LLC, holding 10,408,259 shares of the stock with an approximate value of $22.38 million in ADMA stocks shares; and VANGUARD GROUP INC, currently with $17.5 million in ADMA stock with ownership of nearly -4.074% of the company’s market capitalization.
Positions in ADMA Biologics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 57 institutional holders increased their position in ADMA Biologics Inc. [NASDAQ:ADMA] by around 17,757,504 shares. Additionally, 32 investors decreased positions by around 10,084,632 shares, while 24 investors held positions by with 77,050,314 shares. The mentioned changes placed institutional holdings at 104,892,450 shares, according to the latest SEC report filing. ADMA stock had 24 new institutional investments in for a total of 4,579,186 shares, while 9 institutional investors sold positions of 730,892 shares during the same period.